Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC010041 | Panoply™ Human MYOC Knockdown Stable Cell Line | Inquiry |
| CSC-SC010041 | Panoply™ Human MYOC Over-expressing Stable Cell Line | Inquiry |
| CLOE-0558 | Human MYOC HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD10444Z | Human MYOC adenoviral particles | Inquiry |
| LV19009L | human MYOC (NM_000261) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH213491 | shRNA set against Rat Myoc(NM_030865.1) | Inquiry |
| SHW008193 | shRNA set against Danio rerio MYOC (NM_001015062) | Inquiry |
| SHH213509 | shRNA set against Human MYOC(NM_000261.1) | Inquiry |
| SHH348356 | shRNA set against Human MYOC (NM_000261.1) | Inquiry |
| SHH348360 | shRNA set against Mouse MYOC (NM_010865.3) | Inquiry |
| SHH348364 | shRNA set against Rat MYOC (NM_030865.1) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCL136065 | Human MYOC ORF clone (NM_000261.1) | Inquiry |
| CDFH012087 | Human MYOC cDNA Clone(NM_000261.1) | Inquiry |
| CDFR012397 | Rat Myoc cDNA Clone(NM_030865.1) | Inquiry |
| MiUTR1H-06603 | MYOC miRNA 3'UTR clone | Inquiry |
| MiUTR1R-04095 | MYOC miRNA 3'UTR clone | Inquiry |
| CDCB169668 | Danio rerio MYOC ORF Clone (NM_001015062) | Inquiry |
| CDCB180991 | Rabbit MYOC ORF clone (NM_001082150.2) | Inquiry |
| CDCR249759 | Mouse Myoc ORF Clone(NM_010865.3) | Inquiry |
| CDCR379434 | Rat Myoc ORF Clone(NM_030865.1) | Inquiry |
| CDCS405532 | Human MYOC ORF Clone (BC029261) | Inquiry |
The MYOC gene consists of three exons and two introns, and the three exons are composed of 604, 126 and 782 base pairs, respectively. The 5 kb promoter region contains a number of response elements involved in gene regulation, including: activator protein-1 (AP-1), NFκB, shear stress responsive element (SSRE), Thyroid hormone elements (TRE) and glucocorticoid binding sites. The above-mentioned important motif sequences in the promoter region of TIGR gene are still in the study of the regulation of TIGR gene expression, and it is speculated that these structures are closely related to the influence of environmental/genetic factors on TIGR genes.
The MYOC gene has a cDNA size of 2 kb and its encoded product belongs to mucin/glycoprotein, which exists in both glycosylated and non-glycosylated forms. MYOC is widely expressed in ocular tissues. In addition to the discovery of the MYOC gene in trabecular cells, the cDNA of this gene is also isolated in the ciliary body. The expression of MYOC has been found in tissues such as corneal epithelium, corneal endothelium, corneal stroma, aqueous humor, iris, sclera, ciliary muscle, lens epithelium, sieve plate, retina, and ocular nerve.
Figure 1. Co-aggregation of Grp94 with mutant/misfolded myocilin (80). Grp94, glucose-regulated protein 94. (Wang, H., et al. 2018)
MYOC and Primary Open-angle Glaucoma (POAG)
Studies have shown that there are more than 180 MYOC gene variants, of which about 40 are disease-causing mutations. Most of the disease-causing mutations are clustered on the third exon, less in the first and second exons, and the promoter, intron 1, and intron 2 are also found to have mutations. The primary open-angle glaucoma (POAG) is produced by spreading or aggregating various variant forms of MYOC protein on the endoplasmic reticulum of trabecular meshwork cells. However, changes in wild-type MYOC gene expression do not induce POAG production. MYOC-null mice have neither identifiable effects nor development of glaucoma phenotype during development, suggesting that the MYOC gene is not required for normal intraocular pressure and intraocular morphology. Inhibition of the glycomodulin Grp94 has been reported to be an effective method for the treatment of glaucoma.
Myoc's Pathogenic Mechanism
MYOC is soluble in Triton to form a dimer, and it can also combine with normal cellular components to form a Triton-insoluble polymer, which is involved in the normal physiological activities of the cells. The heterogeneous MYOC combines with other proteins to form macromolecular insoluble aggregates that can cause tissue lysis or cell death. The production of the variant MYOC gene changes the secondary structure of the protein, causing its function to be affected, ultimately leading to the production of POAG. In addition to the accumulation of abnormal MYOC, which can affect the normal function of trabecular meshwork cells, the variation of MYOC in trabecular meshwork cells can cause toxicity and even induce apoptosis of trabecular meshwork cells, which is one of the causes of elevated intraocular pressure. A small amount of MYOC accumulation over a long period of time will cause disease, suggesting that the MYOC secreted by glaucoma patients gradually increases over time. Excessive variation MYOC accumulates in the trabecular meshwork, which also hinders the outflow of aqueous humor and increases intraocular pressure.
References: